PD-1 DNA Antibody Expression for Lower-Cost Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monoclonal antibody therapies targeting the PD-1-PD-L1 signaling pathway for cancer treatment face challenges such as high production costs, stability issues, and the need for frequent high doses, limiting their accessibility and affordability.
Innovation Solution
A recombinant nucleic acid sequence encoding synthetic antibodies, such as PD-1 antibodies or fragments, is administered to generate antibodies in vivo, facilitating rapid assembly and immune response enhancement, potentially reducing treatment costs and increasing efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional monoclonal antibody therapies are administered, then cancer treatment efficacy is improved, but production costs increase and treatment accessibility decreases
Solution Approach 1:
The patent uses DNA sequences encoding antibody variable regions as templates to direct in vivo synthesis of full-length antibodies. The DNA acts as a copy or blueprint that cells use to produce the therapeutic antibody, eliminating the need for expensive external protein manufacturing and purification processes while maintaining therapeutic efficacy
Solution Approach 2:
The patent replaces the mechanical/chemical manufacturing process of protein synthesis and purification with a biological system. By administering DNA sequences that encode antibody variable regions, the patient's own cellular machinery synthesizes the full-length antibodies in vivo, substituting complex biomanufacturing processes with simpler DNA delivery and endogenous protein synthesis
2Reliability
If traditional monoclonal antibody therapies are administered, then cancer treatment efficacy is improved, but treatment frequency increases and patient burden increases
Solution Approach 1:
The patent enables the patient's body to serve itself by using endogenous cellular machinery to synthesize therapeutic antibodies continuously from administered DNA templates. The body's own cells produce the antibodies without requiring repeated external administration, reducing treatment frequency and patient burden while maintaining sustained therapeutic levels
3Productivity
If recombinant protein synthesis is used, then antibody production is achieved, but stability issues and high doses are required
Solution Approach 1:
The patent uses DNA sequences as stable templates that are copied by cellular machinery to produce antibodies. The DNA itself remains stable and persistent in the body, providing continuous instructions for antibody synthesis without the stability problems associated with administering and maintaining recombinant proteins
Solution Approach 2:
The patent performs preliminary encoding of the antibody sequence in stable DNA form before administration. The DNA sequences encoding antibody variable regions are prepared in advance and administered to the patient, where they serve as persistent templates for continuous antibody production, eliminating the need for repeated administration of unstable protein formulations
Data Source
AI summary
Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets programmed cell death protein 1 (PD-1). The disclosure also provides a method of preventing and/or treating disease, such as cancer, in a subject using the composition of the invention.